Aggressive B cell lymphoma
Showing 1 - 25 of >10,000
B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma Trial in Saint Louis (Mosunetuzumab)
Recruiting
- B Cell Lymphoma
- +5 more
-
Saint Louis, MissouriWashington University School of Medicine
Jan 3, 2023
Cardiovascular Events Among Adults Relapsed or Refractory
Recruiting
- Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
- +9 more
- Electronic Health Record Review
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed B-Cell Lymphoma Trial in Saint Louis (Mosunetuzumab,
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- +3 more
- Mosunetuzumab
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Jul 14, 2022
Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive
Active, not recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- fractionated first dose rituximab
-
Geneva, SwitzerlandUniversity Hospital Geneva
Apr 21, 2023
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston
Not yet recruiting
- Refractory Aggressive B-cell Lymphomas
- +12 more
- ACALABRUTINIB
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 13, 2022
Primary Diffuse Large B-cell Lymphoma of the CNS (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS Trial
Suspended
- Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
- Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
- Obinutuzumab
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 6, 2022
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma Trial in China (Rituximab, Etoposide,
Recruiting
- Diffuse Large B Cell Lymphoma
- +2 more
- Rituximab
- +8 more
-
Changsha, Hunan, China
- +5 more
Jan 24, 2022
Lymphoma, B-Cell Trial in Vancouver, Toronto, Montreal (Venetoclax, RiTUXimab Injection, Rituximab SC)
Recruiting
- Lymphoma, B-Cell
- Venetoclax
- +5 more
-
Vancouver, British Columbia, Canada
- +2 more
Jan 24, 2022
Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma Trial in China (Relmacabtagene
Not yet recruiting
- Lymphoma, Large B-Cell, Diffuse
- +3 more
- Relmacabtagene Autoleucel
- +2 more
-
Guangzhou, Guangdong, China
- +12 more
Oct 24, 2023
Lymphoma, Non-Hodgkin Trial in Mainz (Obinutuzumab and Pixantrone)
Completed
- Lymphoma, Non-Hodgkin
- Obinutuzumab and Pixantrone
-
Mainz, RLP, GermanyDepartment of Hematology, Oncology and Pneumology; University Me
Mar 30, 2022
Large B-cell Lymphoma Trial in Tianjin (CNCT19, Gemcitabine Injection, busulfan)
Recruiting
- Large B-cell Lymphoma
- CNCT19
- +3 more
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Jan 24, 2022
B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)
Not yet recruiting
- B-cell Non-Hodgkins Lymphoma (B-NHL)
- (no location specified)
Jan 5, 2023
DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)
Active, not recruiting
- Diffuse Large B-Cell Lymphoma (DLBCL)
- +4 more
- EPOCH
- Rituximab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker
Suspended
- Recurrent Aggressive Non-Hodgkin Lymphoma
- +5 more
- Laboratory Biomarker Analysis
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 12, 2023
Aggressive B-Cell Non-Hodgkin's Lymphoma, Aggressive B-Cell NHL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial
Not yet recruiting
- Aggressive B-Cell Non-Hodgkin's Lymphoma
- +4 more
- (no location specified)
Dec 16, 2022
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate
Recruiting
- Aggressive Non-Hodgkin Lymphoma
- +8 more
- Polatuzumab Vedotin
- +6 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 26, 2023
CNS Lymphoma, Secondary CNS Lymphoma Trial run by the National Cancer Institute (NCI) (TEDD-R, TEDDI-R, Ibrutinib)
Recruiting
- Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma
- TEDD-R
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in United States (IMPT-314)
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
-
Los Angeles, California
- +3 more
Apr 12, 2023
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular
Recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- +19 more
- CD47 Antagonist ALX148
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Spain (ARI0003)
Not yet recruiting
- Refractory Non-Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- ARI0003
-
Santiago De Compostela, A Coruña, Spain
- +6 more
Oct 24, 2023
DLBCL, High Grade B-Cell Lymphoma Trial in United States (Venetoclax, Rituximab, Etoposide)
Completed
- Diffuse Large B-Cell Lymphoma
- High Grade B-Cell Lymphoma
- Venetoclax
- +6 more
-
Boston, Massachusetts
- +5 more
Aug 23, 2022
Non-Hodgkin's Lymphoma Trial in Philadelphia (drug, procedure, genetic)
Completed
- Non-Hodgkin's Lymphoma
- Bendamustine
- +6 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Sep 14, 2022
CLL, SLL, Richter's Transformation Trial in United States (TG-1801, Ublituximab)
Recruiting
- CLL
- +9 more
- TG-1801
- Ublituximab
-
Fayetteville, Arkansas
- +4 more
Jan 20, 2023
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in Spokane, Salamanca (Zilovertamab vedotin,
Recruiting
- Chronic Lymphocytic Leukemia
- +3 more
- Zilovertamab vedotin
- Nemtabrutinib
-
Spokane, Washington
- +1 more
Aug 12, 2022